The ARYx mission is to make proven therapies safer. By applying its retrometabolic approach to pharmaceutical discovery and development, ARYx intends to serve patients by fundamentally improving the safety of oral therapies in large, chronic markets while maintaining their efficacy. To optimize shareholder value, ARYx's goal is to be a profitable company with a continuing pipeline of products, balancing risk against rewards through collaborations with pharmaceutical partners.
Recent Releases
Jul 2, 2008
ARYx Therapeutics, Inc. Announces Successful Results of QT Study on ATI-7505
Jul 2, 2008
ARYx Therapeutics, Inc. Announces Procter & Gamble Exercises Option to End Collaboration on ATI-7505
